Kim M. Tsoi
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Kim M. Tsoi has a total of 113 co-authors. Here are the top co-authors by number of shared publications:
- Anthony Michael Griffin
Division of Orthopaedic Surgery, Mount Sinai Hospital, Toronto, ON M5G 1X5, Canada
23 shared publications - Jay S. Wunder
Division of Orthopaedic Surgery, Mount Sinai Hospital, Toronto, ON M5G 1X5, Canada
23 shared publications - Peter Charles. Ferguson
Division of Orthopaedic Surgery, Mount Sinai Hospital, Toronto, ON M5G 1X5, Canada
21 shared publications - Irene L. Andrulis
Fred A. Litwin Center for Cancer Genetics, Lunenfeld-Tanenbaum Research Institute of Mount Sinai Hospital, Toronto, Ontario, Canada
13 shared publications - Nalan Gokgoz
Lunenfeld-Tanenbaum Research Institute, Sinai Health System, Toronto, ON M5G 1X5, Canada
13 shared publications - Brendan C. Dickson
Department of Laboratory Medicine and Pathobiology, Temerty Faculty of Medicine, University of Toronto, Toronto, Canada
12 shared publications
Latest Publications
- Open Access
- 4 October 2026
- Published by Wiley in Advanced Healthcare Materials
- Vol. 15 (40) , e71792
Cell‐Free DNA as a Biomarker of Cell Death and Treatment Response for On‐Chip Three‐Dimensional Tumor Models
On‐chip 3D cancer models are important tools to investigate treatment response and tumor biology. With their increasing adoption, there is a need for non‐destructive methods that enable the sequential monitoring of cell death and tumor response over time. This study presents quantifying cell‐free DNA (cfDNA) as a proxy for cell death for on‐chip 3D sarcoma models. qPCR analysis of media cfDNA from spheroids and micro‐dissected tumor explants (MDTs) generated from SK‐LMS‐1 and MCA‐205 cell lines cultured on microfluidic chips showed a correlation between baseline cfDNA concentration and on‐chip tumor burden. Furthermore, cfDNA levels increased in a dose‐dependent manner following cytotoxic treatments, including staurosporine and hydrogen peroxide. Single‐dose radiation therapy also raised cfDNA levels in media from MCA‐205 but not SK‐LMS‐1 MDTs, in accordance with their 2D culture response. Finally, cfDNA release within the first days of culture was shown to reflect patient‐derived MDT survival, addressing a critical unmet need for ex vivo culture. This study suggests that media cfDNA quantification could be used as a reliable, non‐disruptive, and rapidly quantifiable measure of cell death for on‐chip 3D models, which facilitates more robust use of 3D model systems for pre‐clinical assessment of treatment‐induced cell death and biological response.
- 4 October 2026
- Published by Wiley in Advanced Healthcare Materials
- Vol. 15 (40) , e71792
Open AccessCell‐Free DNA as a Biomarker of Cell Death and Treatment Response for On‐Chip Three‐Dimensional Tumor Models
On‐chip 3D cancer models are important tools to investigate treatment response and tumor biology. With their increasing adoption, there is a need for non‐destructive methods that enable the sequential monitoring of cell death and tumor response over time. This study presents quantifying cell‐free DNA (cfDNA) as a proxy for cell death for on‐chip 3D sarcoma models. qPCR analysis of media cfDNA from spheroids and micro‐dissected tumor explants (MDTs) generated from SK‐LMS‐1 and MCA‐205 cell lines cultured on microfluidic chips showed a correlation between baseline cfDNA concentration and on‐chip tumor burden. Furthermore, cfDNA levels increased in a dose‐dependent manner following cytotoxic treatments, including staurosporine and hydrogen peroxide. Single‐dose radiation therapy also raised cfDNA levels in media from MCA‐205 but not SK‐LMS‐1 MDTs, in accordance with their 2D culture response. Finally, cfDNA release within the first days of culture was shown to reflect patient‐derived MDT survival, addressing a critical unmet need for ex vivo culture. This study suggests that media cfDNA quantification could be used as a reliable, non‐disruptive, and rapidly quantifiable measure of cell death for on‐chip 3D models, which facilitates more robust use of 3D model systems for pre‐clinical assessment of treatment‐induced cell death and biological response.
- 16 September 2026
- Published by Springer Nature in Skeletal Radiology
- Vol. 56 (1) , 93-109
Perivascular epithelioid cell (PEComa) tumors of the musculoskeletal system: a case series with MR imaging and histopathologic review
- 16 September 2026
- Published by Springer Nature in Skeletal Radiology
- Vol. 56 (1) , 93-109
Perivascular epithelioid cell (PEComa) tumors of the musculoskeletal system: a case series with MR imaging and histopathologic review
- Open Access
- 14 September 2026
- Published by Wiley in Journal of Surgical Oncology
Extended Curettage for Local Control of Chondromyxoid Fibroma: A 33‐Year Experience at a Single Tertiary Center
Background and Objectives: The management of chondromyxoid fibroma (CMF) primarily relies on surgical resection, but simple curettage is reportedly associated with a high local recurrence rate. While extended curettage with high‐speed burring effectively manages other locally aggressive bone tumors, its effectiveness for CMF remains unclear. We aimed to evaluate the outcome of this technique for CMF. Methods: We retrospectively reviewed 31 CMF patients treated at a single tertiary academic hospital between 1990 and 2023. Demographics and treatment details were collected. The primary outcome was local recurrence‐free survival for the patients who underwent extended curettage and had follow‐up for more than 6 months. The secondary outcome was complications. Results: The median age was 41 (IQR, 18–47), and 61% were male. Of the total 31 patients, 26 underwent extended curettage with high‐speed burring, while five underwent en bloc resection. No local recurrence occurred in either group. Among the extended curettage group, 21 had a follow‐up of more than 6 months (median follow‐up: 37 months [IQR, 18–58 months]), only one complication (symptomatic hardware removal) was recorded. Conclusions: Extended curettage with high‐speed burring was associated with excellent local control and few complications, making it a desirable surgical option for CMF.
- 14 September 2026
- Published by Wiley in Journal of Surgical Oncology
Open AccessExtended Curettage for Local Control of Chondromyxoid Fibroma: A 33‐Year Experience at a Single Tertiary Center
Background and Objectives: The management of chondromyxoid fibroma (CMF) primarily relies on surgical resection, but simple curettage is reportedly associated with a high local recurrence rate. While extended curettage with high‐speed burring effectively manages other locally aggressive bone tumors, its effectiveness for CMF remains unclear. We aimed to evaluate the outcome of this technique for CMF. Methods: We retrospectively reviewed 31 CMF patients treated at a single tertiary academic hospital between 1990 and 2023. Demographics and treatment details were collected. The primary outcome was local recurrence‐free survival for the patients who underwent extended curettage and had follow‐up for more than 6 months. The secondary outcome was complications. Results: The median age was 41 (IQR, 18–47), and 61% were male. Of the total 31 patients, 26 underwent extended curettage with high‐speed burring, while five underwent en bloc resection. No local recurrence occurred in either group. Among the extended curettage group, 21 had a follow‐up of more than 6 months (median follow‐up: 37 months [IQR, 18–58 months]), only one complication (symptomatic hardware removal) was recorded. Conclusions: Extended curettage with high‐speed burring was associated with excellent local control and few complications, making it a desirable surgical option for CMF.
- Open Access
Staged Resection with Temporizing VAC and Local Recurrence for Soft Tissue Sarcomas: A Multi-Institutional Review
Background/Objectives: Staged resection with temporizing vacuum-assisted closure (VAC) has been adopted to facilitate margin assessment and local control of soft tissue sarcomas (STS). Accordingly, the objective of this study is to compare rates of local recurrence (LR) among superficial STS patients treated with and without temporizing VAC therapy. Methods: We conducted a multi-institutional retrospective cohort study of superficial STS patients treated at three tertiary care centers. Patients were matched by grade, and descriptive statistics and multivariate binary logistic regression were performed. Results: After matching, 314 superficial STS patients were included in analysis. VAC patients were more likely to present with a history of prior unplanned excision (p = 0.024), with recurrent disease (p = 0.004), harbor a diagnosis of myxofibrosarcoma (p < 0.001), and have positive initial surgical margins (p < 0.001). After multivariate analysis, VAC use remained independently associated with increased LR rates (OR = 4.117; p = 0.003). Conclusions: In this multi-institutional analysis of superficial STS patients, staged resection with temporizing VAC was not associated with improved LR rates. Rather, the VAC cohort represented distinctly higher-risk tumor biology and complex oncologic presentations, in whom the risk of LR may not be fully mitigated by surgical staging alone.
Open AccessStaged Resection with Temporizing VAC and Local Recurrence for Soft Tissue Sarcomas: A Multi-Institutional Review
Background/Objectives: Staged resection with temporizing vacuum-assisted closure (VAC) has been adopted to facilitate margin assessment and local control of soft tissue sarcomas (STS). Accordingly, the objective of this study is to compare rates of local recurrence (LR) among superficial STS patients treated with and without temporizing VAC therapy. Methods: We conducted a multi-institutional retrospective cohort study of superficial STS patients treated at three tertiary care centers. Patients were matched by grade, and descriptive statistics and multivariate binary logistic regression were performed. Results: After matching, 314 superficial STS patients were included in analysis. VAC patients were more likely to present with a history of prior unplanned excision (p = 0.024), with recurrent disease (p = 0.004), harbor a diagnosis of myxofibrosarcoma (p < 0.001), and have positive initial surgical margins (p < 0.001). After multivariate analysis, VAC use remained independently associated with increased LR rates (OR = 4.117; p = 0.003). Conclusions: In this multi-institutional analysis of superficial STS patients, staged resection with temporizing VAC was not associated with improved LR rates. Rather, the VAC cohort represented distinctly higher-risk tumor biology and complex oncologic presentations, in whom the risk of LR may not be fully mitigated by surgical staging alone.
- 11 October 2025
- Published by Springer Nature in Skeletal Radiology
- Vol. 55 (2) , 425-438
Clinical and magnetic resonance imaging features of soft tissue extraskeletal myxoid chondrosarcoma: A retrospective observational cohort study
Objectives To review the MRI, histological, and clinical features of extraskeletal myxoid chondrosarcoma (EMC). Methods Retrospective review of pre-treatment MRIs in 44 patients with pathologically proven EMC. Patient demographics, tumor MR-imaging features, histology and gene rearrangements, clinical management, and follow-up were reviewed. MRI features assessed included lesion size, location, morphology, signal characteristics, and relation to adjacent structures. Correlative analysis was performed to assess associations between demographic, clinical, molecular, and MRI variables with metastatic disease. Results EMCs were predominantly located in the lower extremity (38/44, 86%) and deep-to-fascia (36/44, 82%). All lesions (44/44) demonstrated well-circumscribed margins. Mean maximal dimension was 8.8 cm (range 1.7–36 cm); 93% (41/44) of lesions were hyperintense on fat-suppressed T2-weighted/ STIR imaging. Post-contrast enhancement was “solid” (> 80% enhancement) in 18%, “mixed” (20–80% enhancement) in 53%, and “sparse” (< 20% enhancement) in 29%. Nodal metastases were detected on preoperative imaging in four patients (9%), and pulmonary metastases in three cases preoperatively, and five cases postoperatively (range 14–128 months). EWSR1::NR4A3 fusion rearrangements were documented in 25 tumors (57%), and non-EWSR1 NR4A3 fusions in six cases (14%). The only variable demonstrating a significant correlation with metastatic disease was “solid” pattern of lesional enhancement (p = 0.035). Conclusions EMC is most commonly a deep lesion of the extremities demonstrating hyperintense T2-weighted signal, internal septations, and variable patterns of enhancement on MRI. Nodal disease is relatively frequent, and prolonged surveillance is recommended as metastases may develop years after diagnosis. Although analysis is limited by small case numbers, a “solid” (> 80%) pattern of enhancement was significantly associated with metastatic disease.
- 11 October 2025
- Published by Springer Nature in Skeletal Radiology
- Vol. 55 (2) , 425-438
Clinical and magnetic resonance imaging features of soft tissue extraskeletal myxoid chondrosarcoma: A retrospective observational cohort study
Objectives To review the MRI, histological, and clinical features of extraskeletal myxoid chondrosarcoma (EMC). Methods Retrospective review of pre-treatment MRIs in 44 patients with pathologically proven EMC. Patient demographics, tumor MR-imaging features, histology and gene rearrangements, clinical management, and follow-up were reviewed. MRI features assessed included lesion size, location, morphology, signal characteristics, and relation to adjacent structures. Correlative analysis was performed to assess associations between demographic, clinical, molecular, and MRI variables with metastatic disease. Results EMCs were predominantly located in the lower extremity (38/44, 86%) and deep-to-fascia (36/44, 82%). All lesions (44/44) demonstrated well-circumscribed margins. Mean maximal dimension was 8.8 cm (range 1.7–36 cm); 93% (41/44) of lesions were hyperintense on fat-suppressed T2-weighted/ STIR imaging. Post-contrast enhancement was “solid” (> 80% enhancement) in 18%, “mixed” (20–80% enhancement) in 53%, and “sparse” (< 20% enhancement) in 29%. Nodal metastases were detected on preoperative imaging in four patients (9%), and pulmonary metastases in three cases preoperatively, and five cases postoperatively (range 14–128 months). EWSR1::NR4A3 fusion rearrangements were documented in 25 tumors (57%), and non-EWSR1 NR4A3 fusions in six cases (14%). The only variable demonstrating a significant correlation with metastatic disease was “solid” pattern of lesional enhancement (p = 0.035). Conclusions EMC is most commonly a deep lesion of the extremities demonstrating hyperintense T2-weighted signal, internal septations, and variable patterns of enhancement on MRI. Nodal disease is relatively frequent, and prolonged surveillance is recommended as metastases may develop years after diagnosis. Although analysis is limited by small case numbers, a “solid” (> 80%) pattern of enhancement was significantly associated with metastatic disease.
- Open Access
- 15 September 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Figure 1 from Optimal Factors That Influence the Establishment of Successful Primary Human Soft-Tissue Sarcoma Cell Lines
Supplementary Figure 1. A Kaplan-Meier overall survival (OS) curve based on STS type for 136 patients who gave primary specimens and had available follow up information
- 15 September 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure 1 from Optimal Factors That Influence the Establishment of Successful Primary Human Soft-Tissue Sarcoma Cell Lines
Supplementary Figure 1. A Kaplan-Meier overall survival (OS) curve based on STS type for 136 patients who gave primary specimens and had available follow up information
- Open Access
- 15 September 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Figure 2 from Optimal Factors That Influence the Establishment of Successful Primary Human Soft-Tissue Sarcoma Cell Lines
Supplementary Figure 2. Kaplan-Meier disease-free survival (DFS) curves for patients who gave primary specimens and did not present with recurrent disease by STS type for A) LMS (n = 55), B) MFS (n = 26), and C) UPS (n = 40) patients based on cell line growth.
- 15 September 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure 2 from Optimal Factors That Influence the Establishment of Successful Primary Human Soft-Tissue Sarcoma Cell Lines
Supplementary Figure 2. Kaplan-Meier disease-free survival (DFS) curves for patients who gave primary specimens and did not present with recurrent disease by STS type for A) LMS (n = 55), B) MFS (n = 26), and C) UPS (n = 40) patients based on cell line growth.
- Open Access
- 15 September 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Table 4 from Optimal Factors That Influence the Establishment of Successful Primary Human Soft-Tissue Sarcoma Cell Lines
Supplementary Table 4. Short tandem repeat profiling of 40 cases with bulk specimens and cell line materials available for 10 loci.
- 15 September 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table 4 from Optimal Factors That Influence the Establishment of Successful Primary Human Soft-Tissue Sarcoma Cell Lines
Supplementary Table 4. Short tandem repeat profiling of 40 cases with bulk specimens and cell line materials available for 10 loci.
- Open Access
- 15 September 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Table 2 from Optimal Factors That Influence the Establishment of Successful Primary Human Soft-Tissue Sarcoma Cell Lines
Supplementary Table 2. Characteristics of primary specimens used to initiate cell lines by type.
- 15 September 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table 2 from Optimal Factors That Influence the Establishment of Successful Primary Human Soft-Tissue Sarcoma Cell Lines
Supplementary Table 2. Characteristics of primary specimens used to initiate cell lines by type.
- Open Access
- 15 September 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Table 5 from Optimal Factors That Influence the Establishment of Successful Primary Human Soft-Tissue Sarcoma Cell Lines
Supplementary Table 5. The histology of the human primary specimens and corresponding xenograft specimens as reviewed by an expert pathologist.
- 15 September 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table 5 from Optimal Factors That Influence the Establishment of Successful Primary Human Soft-Tissue Sarcoma Cell Lines
Supplementary Table 5. The histology of the human primary specimens and corresponding xenograft specimens as reviewed by an expert pathologist.